Trevi Therapeutics, Inc. - Common Stock (NQ:TRVI)

14.53 +0.21 (+1.43%)

Delayed Quote Updated: 2:21 PM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Trevi Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Trevi Therapeutics Q2 Earnings Call Highlights ↗

August 07, 2026

Trevi Therapeutics (NASDAQ:TRVI) said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio,...

Via MarketBeat

Topics Earnings

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗

June 03, 2026

This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.

Via The Motley Fool

Topics Regulatory Compliance

Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 ↗

May 09, 2026

Trevi Therapeutics (NASDAQ:TRVI) outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming...

Via MarketBeat

Trevi Therapeutics Inc. (NASDAQ:TRVI) Beats Q4 2025 EPS Estimates, Gains FDA Alignment for Phase 3 Program ↗

March 17, 2026

Via Chartmill

Earnings Scheduled For November 13, 2025 ↗

November 13, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Earnings Preview For Trevi Therapeutics ↗

May 07, 2025

Via Benzinga

As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗

March 23, 2026

This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.

Via The Motley Fool

Trevi Therapeutics (TRVI) Earnings Transcript ↗

March 18, 2026

Trevi Therapeutics (TRVI) Earnings Transcript

Via The Motley Fool

TRVI Stock Slips After Company Plans Parallel Trials In Lung Disease — Stifel Dismisses Timeline Concerns ↗

March 09, 2026

The company announced its decision following a meeting with the U.S. Food and Drug Administration.

Via Stocktwits

MarketBeat’s Top 5 Rated Small-Cap Stocks ↗

December 22, 2025

Via MarketBeat

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

December 03, 2025

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 28, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 27, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

November 27, 2025

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗

November 27, 2025

Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.

Via The Motley Fool

Topics Regulatory Compliance

Trevi Therapeutics Inc (NASDAQ:TRVI) Reports Q3 2025 Results, Narrows Loss and Outlines Phase 3 Plans ↗

November 13, 2025

Trevi Therapeutics reported a narrower-than-expected Q3 2025 loss. The biopharma firm is preparing its Phase 3 program for Haduvio and has cash into 2028.

Via Chartmill

A Peek at Trevi Therapeutics's Future Earnings ↗

November 12, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 03, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 09, 2025

Via Benzinga

This Adient Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

August 21, 2025

Via Benzinga

Dow Gains Over 100 Points; US Job Openings Increase In April ↗

June 03, 2025

Via Benzinga

Topics Stocks

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients ↗

June 02, 2025

Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant results at multiple doses.

Via Benzinga

Earnings Scheduled For March 18, 2025 ↗

March 18, 2025

Via Benzinga

Unusual volume stocks are being observed in Tuesday's session. ↗

March 11, 2025

In today's session, these stocks are experiencing unusual volume.

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

March 10, 2025

The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday ↗

March 10, 2025

Via Benzinga

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps ↗

March 10, 2025

Trevi's Haduvio met the primary endpoint in a Phase 2a trial, showing a significant reduction in cough frequency with no serious adverse events reported.

Via Benzinga

Top movers in Monday's pre-market session ↗

March 10, 2025

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.